阿托伐他汀调节2型糖尿病患者低密度脂蛋白胆固醇及载脂蛋白B的系统评价

目的系统评价阿托伐他汀调节中老年2型糖尿病患者低密度脂蛋白胆固醇(LDL-C)及载脂蛋白B(apoB)的效果。方法计算机检索PubMed(1990～2009),Cochrane Library(1990～2010),Elsevier(2000～2010),维普(1989～2010),中国生物医学文献数据库(2000～2010),中国学术期刊全文数据库(1990～2010),万方数据库(1990～2010),手工检索中华糖尿病杂志(2001～2010),中华内分泌代谢杂志(2001～2010)。按纳入与排除标准选择随机对照试验(RCT)。评价质量及提取资料后,采用RevMan 5.0.1软件对数据进行Meta分析。结果共纳入4项随机对照试验中的3171例糖尿病患者,Meta分析结果显示阿托伐他汀可使中老年2型糖尿病患者LDL-C下降WMD=-1.00,95%CI(-1.37～-0.64),P<0.01]。阿托伐他汀组较安慰剂组apoB下降WMD=-0.34,95%CI(-0.50～-0.17),P<0.01]。结论中老年2型糖尿病患者长期服用小剂量的阿托伐他汀有助调节LDL-C及apoB代谢,改善脂代谢紊乱。

Effects of atorvastatin on LDL-C and apoB in patients with type 2 diabetes mellitus: a systematic review

Objective To assess the efficacy of atorvastatin for regulating LDL-C and apoB in type 2 diabetes mellitus. Methods Electronic search of Pubmed,The Coehrane Library, Elsevier, VIP,and manual search of the China Biological Medicine Database and The Wangfang Data to 2010 were done. Randomized controlled trials of atorvastatin therapy for type 2 diabetes mellitus were included. Meta-analyses were performed for the results of homogeneous studies using the Cochrane Collaboration RevMan 5. 0. 1 software. Results Four trials with a total of 3171 patients with type 2 diabetes mellitus were included. The meta-analyses showed that atorvastatin could lower the LDL-C WMD= -1.00,95%CI （ -1.37,-0.64）,P〈0.01]and apoBWMD= -0.34,95%CI （ -0.50, -0.17）, P 〈 0.01 ] in plasma in type 2 diabetes mellitus. Conclusion This meta-analysis results suggest that low-dose atorvastatin in long-term have positive effects on the adjustment of LDL-C and apoB, as well as improving blood lipid in patients with type 2 diabetes mellitus.